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http://dx.doi.org/10.1016/j.stemcr.2016.06.009SUMMARYBonemarrowniches for hematopoietic progenitor cells are not well defined despite their critical role in blood homeostasis.We previously
found that cells expressing osteocalcin, amarker ofmature osteolineage cells, regulate the production of thymic-seeding T lymphoid pro-
genitors. Here, using a selective cell deletion strategy, we demonstrate that a subset of mesenchymal cells expressing osterix, a marker of
bone precursors in the adult, serve to regulate the maturation of early B lymphoid precursors by promoting pro-B to pre-B cell transition
through insulin-like growth factor 1 (IGF-1) production. Loss of Osx+ cells or Osx-specific deletion of IGF-1 led to a failure of B cell matu-
ration and the impaired adaptive immune response. These data highlight the notion that bone marrow is a composite of specialized
niches formedby pairings of specificmesenchymal cells with parenchymal stemor lineage committed progenitor cells, thereby providing
distinctive functional units to regulate hematopoiesis.INTRODUCTION
Characterization of the niche has provided insight into
molecular pathways modulating stem cell function for
tissue regeneration and cancer. Although the multitude of
cells comprising bone marrow stroma remains incom-
pletely defined (Yu and Scadden, 2016a), recent studies
indicate that while primitive mesenchymal progenitors
are more critical for hematopoietic stem cell (HSC) func-
tion, lineage-restricted mesenchymal cells control more
committed hematopoietic progenitors (Mendez-Ferrer
et al., 2010). Specifically, it was described that the deletion
of a range of osteolineage cells or CXCL12 from these cells
alters B cell progenitors (Greenbaum et al., 2013; Visnjic
et al., 2004) or B and T cell counts (Ding and Morrison,
2013). Furthermore, deletion of osteocytes created sys-
temic disruption of metabolism and affected thymic func-
tion (Sato et al., 2013).
These data suggest that niches are not limited to the
governance of stem cells (Wu et al., 2009; Yu et al.,
2015a), and the definition of ‘‘progenitor niches’’ may offer
new ways to understand the regulation of tissue composi-
tion and function.We recently demonstrated that selective
deletion of cells expressing the mature osteolineage cell
marker Osteocalcin (Ocn) results in decreased T competent
common lymphoid progenitors (CLPs) with a minimal
effect on B cell-biased CLPs (Ly6D+) (Yu et al., 2015a)
due to a defective generation of thymic-seeding progen-
itor cells. The mutant phenotype was recapitulated by se-220 Stem Cell Reports j Vol. 7 j 220–235 j August 9, 2016 j ª 2016
This is an open access article under the CC BY-NC-ND license (http://creativlective deletion of DLL4 in Ocn+ cells, or of its receptor
and downstream signaling molecules in primitive hemato-
poietic cells; therefore Ocn+ cells constitute a regulatory
niche guiding the production and differentiation of he-
matopoietic cells contributing to T cell neogenesis.
Given that others using genetic constructs to disrupt a
broad range of osteolineage cells showed a decrease in
mature B cells (Ding and Morrison, 2013; Visnjic et al.,
2004; Wu et al., 2008), that B cells are adjacent to
CXCL12-abundant reticular (CAR) cells (Omatsu et al.,
2010), and that continuous deletion of CXCL12 in devel-
opment using Osx-Cre leads to reduced B cell production
(Greenbaum et al., 2013), we hypothesized that Osx+ cells
may serve as a B cell differentiation modulator in adult
animals. We sought to determine this using a cell-type-
specific in vivo cell-ablation strategy.
The perceived hierarchy of bone cell differentiation be-
gins from the multipotent mesenchymal stem cell, which
matures to become the osteoprogenitor, the pre-osteoblast,
the mature osteoblast and/or the lining cell, and even-
tually the terminally differentiated osteocyte. While less
is known regarding the heterogeneity of the mesenchymal
stem cell population (Yu and Scadden, 2016b) andmultiple
markers such as Leptin receptor (Zhou et al., 2014), Nestin
(Ono et al., 2014), and Gremlin1 (Worthley et al., 2015),
and Mx1(Park et al., 2012) among others (Chan et al.,
2015) had been recently proposed to label mesenchymal
stem cell populations of various regenerative properties,
markers for osteoprogenitor and mature osteoblast areecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. A Triple Transgenic Mouse to Study the Dynamics of Osteolineage Subpopulations
(A) Osterix-Cre (OsxCre) mice were crossed with the Rosa26-loxP-stop-loxP-mCherry reporter mice (Rosa-mCh), which express mCherry
fluorescent protein upon Cre-mediated excision of a stop sequence. OsxCre+;Rosa-mCh+ mice were then crossed with the osteocalcin-
Topaz (Ocn:Topaz) mice. Upon tamoxifen injection into the OsxCre+;Rosa-mCh+;Ocn:Topaz+ mice, the Osx+ cells and their progeny are
labeled red, whereas the Ocn+ cells are labeled green. Cells that express osterix following tamoxifen injection and produce osteocalcin
are yellow.
(B) Osx+, Ocn+, and ++ cells were enumerated in femur sections of OsxCre+;Rosa-mCh+;Ocn:Topaz mice at the indicated time points
following tamoxifen injection.
(legend continued on next page)
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more clearly defined. Osterix (Osx/Sp7) is a zinc finger-con-
taining transcription factor expressed in osteoprogenitors
and serves as a key regulator of osteolineage differentiation
(Mizoguchi et al., 2014; Nakashima et al., 2002).Osteocalcin
(Ocn) is the most well-characterized extracellular matrix
protein expressed by mature osteoblasts. However, these
markers were mostly used in independent studies,
rendering it difficult to study the dynamic relationship of
osteolineage subsets in vivo. Here, we generated a triple
transgenic mouse that differentially labels Osx+ and Ocn+
cells. We used this model to interrogate whether distinct
osteolineage subsets serve to regulate different hematopoi-
etic processes.RESULTS
We examined whether the Osx+ cells could be distin-
guished from Ocn+ cells in vivo for an interval sufficient
to test their distinctive biological function. Mice car-
rying a fusion of Cre and modified estrogen receptor
under the control of the Osterix promoter (Osx-CreERt2
[Maes et al., 2010]), hereafter called OsxCre, were crossed
with mice bearing a Rosa26-loxP-stop-loxP-mCherry
(Rosa-mCh) transgene (OsxCre;Rosa-mCh) (Strecker et al.,
2013). Administration of 4-hydroxy-tamoxifen (4-OHT)
to OsxCre+;Rosa-mCh+ mice resulted in Cre activation
in Osx+ cells followed by excision of the stop cassette and
production of the mCherry fluorophore. Upon 4-OHT in-
jection, the red fluorescence marks cells expressing OSX
as well as their progeny. These mice were crossed with
mice expressing the GFP, Topaz, driven by the Osteocalcin
promoter (Ocn:Topaz) (Bilic-Curcic et al., 2005). In this tri-
ple transgenic model (OsxCre+;Rosa-mCh+;Ocn:Topaz+),
the OCN-expressing cells are green, the OSX-expressing
cells (and their descendants) are red, and cells expressing
both markers are yellow (Figure 1A). According to osteoli-
neage ontology, we anticipated that the Osx+ osteopro-
genitors initially labeled red would become yellow as
they express OCN. Six-week-old OsxCre+;Rosa-mCh+
mice were pulsed with an injection of tamoxifen (day 0)
and fluorescent cells were quantified over time. In a
6-week chase, a modest number of dual-labeled (++) cells
emerged (0.02% of total bone cells) (Figure 1B), but thema-
jority of cells were either mCherry (OSX+) or Topaz (OCN+)
single positive (Figure 1C). Cells labeled as ++were found at
themetaphyseal region, located near the endosteal surface.(C) Representative sections of an OsxCre+;Rosa-mCh+;Ocn:Topaz+ mou
different osteolineage subsets. Blue indicates DAPI, red mCherry (Osx+
and red arrow points to Osx+ cells. BT, bone, trabecular; BM, bone m
rescence. Scale bar, 75 mm.
Experiment repeated once, n = 4/group/experiment (B and C).
222 Stem Cell Reports j Vol. 7 j 220–235 j August 9, 2016These data show that Osx+ cells do not necessarily transi-
tion to Ocn+ cells over a 6-week period, although a modest
number of cells do. It may be that limited efficiencies of
fluorophore expression underestimate the cells transition-
ing from Osx to Ocn expression. Also possible is that
some OSX labeling occurs in cells that do not proceed to
osteoblasts expressing OCN or that dually labeled cells
are lost due to disadvantageous characteristics from dual
fluorophore production. Nonetheless, this triple transgenic
system enables us to isolate distinct subpopulations of the
osteolineage within the same animal by flow cytometry
and allows subsequent characterization of their molecular
and functional profiles.
We then assessed the three labeled populations. At day 4
after 4-OHT treatment, Osx+, ++, and Ocn+ cells were puri-
fied by fluorescence-activated cell sorting from bone cell
suspensions isolated from the triple transgenic model,
and subjected to gene-expression profiling by microarray.
Principal component analysis of the 2,509 top genes clus-
tered together Osx+ and ++ cells as more similar compared
with Ocn+ cells (data not shown). Restrictive filtering re-
vealed the top 25 differentially expressed genes among
the three populations (Table S1). Gene ontology analysis
revealed that genes upregulated in Ocn+ cells were related
to cell adhesion and cytokines, whereas Osx+ cells highly
transcribe genes involved in extracellular matrix interac-
tion and Hedgehog-dependent pathways (Table S2). Inter-
estingly, the ++ population represented a well-defined
population with distinctive expression of pro-inflam-
matory cytokines and macrophage-related surface and
secreted molecules. Microarray results were validated by
RT-PCR on sorted Osx+, ++, and Ocn+ cells (Figure S1A).
We investigated whether Osx+, Ocn+, or ++ cells have
unique effects on hematopoietic stem and progenitor cell
(HSPC) function ex vivo. Six days following 4-OHT injec-
tion into 4- to 6-week-old triple transgenic mice, FACS
sorted Osx+, ++, or Ocn+ cells were separately co-cultured
for 5 days with purified HSPCs (LINEAGElo, C-KIT+,
SCA-1+, CD150+, CD48) isolated from GFP+ mice.
Following co-culture, cells were transplanted into lethally
irradiated recipients (Figure S1B). HSPCs co-cultured with
each osteolineage subset maintained their long-term
reconstitution and multilineage potential (Figure S1C).
However, HSPCs co-cultured with Osx+ cells displayed
increased total chimerism compared with those co-
cultured with Ocn+ and ++ cells at 4 weeks, and improved
chimerism comparedwith ++ cells at 16weeks (Figure S1C).se 4–6 weeks after tamoxifen injection showing the location of the
cells), and green Topaz (Ocn+ cells). Yellow arrow indicates ++ cells
arrow cavity. Note the punctated appearance of the mCherry fluo-
AD
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Figure 2. Osx+ Cell-Specific Deletion In Vivo without Altering Osteoclastogenesis
(A and B) Skeletal development in the OsxCre;iDTR mutants compared with control littermates at 6 weeks of age. Three independent
experiments; n = 9–15/group. ***p < 0.001.
(legend continued on next page)
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B lymphoid cells (B220+ cells) were the major contributors
to the increased engraftment from HSPCs co-cultured with
Osx+ cells (Figure S1D), while there was short-term
enhanced reconstitution of T cells (CD4+ and CD8+ cells)
at 8 weeks, and this effect disappeared at 12 and 16 weeks
(Figure S1E). No difference was observed for the Mac/
Gr1+ subset (Figure S1F).
We next postulated whether Osx+ cell regulates B cell
populations in vivo using a selective cell-depletion model.
We crossed the Osx1-GFP::Cre mice with the iDTR mice
(hereafter OsxCre;iDTR), in which ubiquitous expression
of the diphtheria toxin receptor (iDTR) is blocked by a
LoxP-flanked STOP sequence. Cre-mediated excision of
the STOP sequence allows expression of the iDTR in select
cell populations that then become susceptible to killing
upon peritoneal administration of diphtheria toxin (DT).
We began dailyDT injections into both control andmutant
mice starting at 4 weeks of age. At 6 weeks, there was a
striking difference of skeletal size when we compared
the OsxCre+;iDTR+/+ controls with the OsxCre+;iDTRFl/+
mutants (Figures 2A and 2B). OsxCre+;iDTRFl/+ mutants
showed reduced bone mass (Figures 2C and 2D) and osteo-
blastic functions including reduced bone formation, serum
levels of osteocalcin, and type I procollagen production
(Figure 2D). Flow cytometry revealed a 50% reduction
of Osx+ cells in mutants (Figure 2E). To assure targeted
cell deletion, we examinedDTR inmutant animals without
toxin injection by immunohistochemistry. Expression of
the DTR strongly overlapped with staining of OSX in
the OsxCre+;iDTRFl/+ animals (Figures S2A–S2J). Of note,
OsxCre+;iDTRFl/+ animals did not display extensive over-
lapping with OCN staining, confirming our observations
from the lineage-tracing experiments. Staining of bone sec-
tions with OSX-specific antibodies in combination with
TUNEL staining confirmed that the targeted osteolineage
cells were correctly deleted (Figure 2F). Tartrate-resistant
acid phosphatase (TRAP) staining and measurement of
degraded collagen confirmed that osteoclastogenesis
was not affected (Figure 2G). These data indicate that a
distinct subset of osteolineage cells were depleted in the
OsxCre+;iDTRFl/+ mouse and that we were able to selec-
tively assess the impact of these Osx+ cells for a time lapse
following cell deletion. We asked whether selective dele-(C) Histology of femurs from OsxCre;iDTR control and mutant mice. T
(D and E) Bone histomorphometric measurement on trabecular numb
rate, serum production of osteocalcin, and type I procollagen produc
**p < 0.01. (E) Flow cytometric quantification of Osx+ cells in control a
(F) Bone sections were stained with osterix-specific antibody overlapp
Three independent experiments; n = 9–15/group.
(G) Measurement of osteoclast number as indicated by TRAP staini
breakdown in sera. Two independent experiments; n = 22–24/group.
Error bars represent ± SEM.
224 Stem Cell Reports j Vol. 7 j 220–235 j August 9, 2016tion of Osx+ cells might lead to a compensatory expansion
ofmore primitive bone progenitor cells, thereby confound-
ing our interpretation. Colony-forming unit osteoblast
(CFU-Ob) assays failed to detect any increase in primitive
mesenchymal progenitors between controls and mutants
(Figure S2K). However, other non-hematopoietic cell types
might be affected by Osx+ cell depletion and influence the
hematopoietic phenotype observed.
Despite the dramatic changes in bone morphology in
OsxCre;iDTR mutants, bone marrow cellularity was unaf-
fected compared with their control littermates (Figure 3A).
Red blood cell and platelet numbers were unchanged in
the blood of the OsxCre;iDTR mutant, but there was a
50% decrease in the white blood cell count due to severe
lymphopenia (Figure 3B). The mutant bone marrow had
fewer mature B220+IgM+ B cells, increased monocytes
and granulocytes (Figure 3A), and a corresponding in-
crease in granulocyte and macrophage progenitors
(GMPs) (Figure 3C). Given the importance of the spleen
for B lymphopoiesis and extramedullary hematopoiesis,
we analyzed the spleens and noted no difference in
weight, but similarly increased Mac1+Gr1+ cells in the
OsxCre;iDTR mutants (Figure 3D). In summary, Osx+ cell
deletion caused a loss of mature B cells and an increase
in myeloid cells in both the bone marrow and spleen of
mutant animals.
We assessed whether the GMP increase in the OsxCre;
iDTR mutants was secondary to increased proliferation or
decreased death of GMPs. There was change in neither
cell-cycle status (Figure S3A) nor apoptosis (Figure S3B).
The accumulation of GMP and Mac1+Gr1+ cells could
either be an osteoprogenitor-mediated hematopoietic
effect or a consequence of inflammatory phagocytic-type
immune response triggered by the death of osteolineage
cells. To test this hypothesis, we co-injected indomethacin,
a non-steroidal anti-inflammatory drug, together with
DT in OsxCre;DTR mutant mice for 1 week. Bone marrow
analysis revealed normalization of the GMP, Mac1+, and
Mac1+Gr1+ cell populations in indomethacin-treated ani-
mals (Figure S3C). Therefore, the increase in Mac1+Gr1+
myeloid cells could be due to inflammatory response to
osteolineage cell death, although we cannot exclude an
osteolineage cell-mediated myeloid effect.hree independent experiments; n = 9–15/group.
er, trabecular separation, number of osteoblasts, bone formation
tion. Three independent experiments; n = 9–15/group. *p < 0.05,
nd mutant groups. Three independent experiments; n = 9–15/group.
ed with apoptotic TUNEL staining to confirm targeted cell deletion.
ng, and osteoclast activity, as indicated by the rate of collagen
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Figure 3. Osx+ Cell Ablation Causes B lymphopenia and an Increase in Monocytes and Macrophages
(A) Flow cytometric measurement of bone marrow cellularity and multiple mature lineages in OsxCre;iDTR mutants compared with control
littermates.
(B) White blood cell, red blood cell, and platelet counts in the peripheral blood of OsxCre;iDTR mutants versus controls.
(C) Enumeration of different progenitor subtypes in the bone marrow.
(D) Examination of the spleen as a major site for B lymphopoiesis and extramedullary hematopoiesis showed a similar increase in
Mac1+Gr1+ myeloid cells and attenuated mature B cell number.
Experiment repeated 2–3 times; n = 4–12/group. *p < 0.05, ***p < 0.001. Error bars represent ± SEM.We asked whether HSC function was affected by the
short-term deletion of Osx+ cells. We observed no differ-
ences between the OsxCre;iDTR mutants and controls in
long-term HSC (LINloC-KIT+SCA-1+CD48CD150+) num-
ber (Figure S4A), proliferation (Figure S4B), or apoptosis
(Figure S4C). There was an increase in LINloC-KIT+SCA-1
progenitor cell number and cell cycle (Figures S4A and
S4B). However, no defect in HSC function was detected
when bone marrow cells from were transplanted into pri-
mary and secondary recipients in a 1:1 ratio with congenic
SJL competitor cells (Figure S4D). These data suggest that
short-term deletion of Osx+ cells did not affect HSC
function.
Given the diminished production of mature B cells,
we assessed CLPs and found no difference (Figure 3C).
However, intermediate stages of B cell development were
affected. Specifically, a decrease in both pre-B and mature
B populations were noted while pro-B cells, especially dur-
ing the later C0 pro-B andC00 pro-B stages, were significantly
increased (Figure 4A). These data strongly suggest thatB cell differentiation was impaired at the pro-B to pre-B
juncture.
We next tested whether these changes affected the
animal’s immune response. Mice were challenged with
NP-Ficoll to trigger a T cell-independent (Maizels et al.,
1988) immune response and followed for 28 days. Data re-
vealed that OsxCre;iDTRmutants could not sustain immu-
noglobulin G (IgG) and M (IgM) production over time
compared with their control littermates (Figures 4B and
4C). These data indicate that the perturbation in B cell
development was not simply immunophenotypic, but
there was also a functional reduction in Ig production
and immune response.
To determine whether the B cell differentiation defect
was microenvironment-dependent, we transplanted 1 3
106 bonemarrow cells from congenic SJLmice into lethally
irradiated control or mutant OsxCre;iDTR recipients. A
similar rate of reconstitution was seen in both control
andmutants (Figure 5A). As wild-type SJL cells repopulated
both control and mutant OsxCre;iDTR recipients over theStem Cell Reports j Vol. 7 j 220–235 j August 9, 2016 225
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Figure 4. Osx+ Cell Deletion Leads to Blockade of pro-B to pre-B Transition and Impairs Adaptive Immunity
(A) Analysis of intermediate stages of B cell maturation in the OsxCre;iDTR mutants compared with control littermates.
(B and C) Animals were challenged with NP-Ficoll to produce immunoglobulins in a T cell-independent manner. Production of IgG (B) and
IgM (C) were assessed over 28 days.
Three independent experiments; n = 12–16/group. *p < 0.05, **p < 0.01, ***p < 0.001. Error bars represent ± SEM.next 12 weeks, we observed a gradual recapitulation of
the OsxCre+/;DTRFl/+ hematopoietic phenotype in the
mutant recipients but not in the controls (Figures 5B–5F).
These data strongly suggest that the incomplete B cell
differentiation observed in OsxCre;iDTR was caused by
an altered bone microenvironment.226 Stem Cell Reports j Vol. 7 j 220–235 j August 9, 2016To confirm this, we transplanted mutant cells into wild-
type hosts in a reverse transplant setting. Either 5 3 105
OsxCre;iDTR mutant or control bone marrow cells,
competed with 53 105 SJL bonemarrow cells in a 1:1 ratio,
were transplanted into lethally irradiated SJL hosts. When
cells from OsxCre;iDTR mutant mice were competed with
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Figure 5. Osx+ Cell Controls B Lympho-
poiesis through a Microenvironment-
Dependent Effect
(A–F) Transplantation of wild-type cells
into mutant hosts. 1 3 106 total bone
marrow cells from wild-type congenic
SJL mice (CD45.1) were transplanted
into lethally irradiated control or mutant
OsxCre;iDTR recipients (CD45.2). (A) A
similar rate of reconstitution was seen in
both control and mutant groups. (B–F) As
wild-type hematopoietic cells repopulated
the new hosts over the next 12 weeks,
we observed a gradual re-creation of the
OsxCre;iDTR mutant hematopoietic pheno-
type in the mutant recipients but not in the
control group.
(G–L) Transplantation of mutant cells into
wild-type hosts. Bonemarrow cells (53 105)
from either control or mutant OsxCre;iDTR
mice were competed with wild-type 53 105
SJL bone marrow competitors in a 1:1 ratio,
and transplanted into lethally irradiated
SJL hosts. (G) No functional disadvantage
was seen in reconstitution when OsxCre;
iDTR mutant cells competed with wild-type
cells. (H–L) When hematopoietic cells from
OsxCre;iDTR mutant donors were placed into
a wild-type microenvironment, the hemato-
poietic defect was normalized over time.
Two independent experiments; n =10/group/
experiment. *p < 0.05, **p < 0.01. Error bars
represent ± SEM.cells from wild-type mice, no functional disadvantage was
seen during reconstitution (Figure 5G). In addition, when
hematopoietic cells from OsxCre;iDTR mutant donorswere transplanted into a wild-type host, the hematopoietic
defect was normalized over time (Figures 5H–5L). Thus
the hematopoietic defect observed in the OsxCre;iDTRStem Cell Reports j Vol. 7 j 220–235 j August 9, 2016 227
mutants was not cell autonomous, but caused by alteration
in the microenvironment.
To assesswhich secreted factors released by osteoprogeni-
tors mediate B cell differentiation, we compared local cyto-
kines within the bonemarrow of OsxCre;iDTRmutant and
control mice by cytokine array. Since we observed a pro-B
to pre-B differentiation blockade in the OsxCre;iDTR mu-
tants, and interleukin-7 (IL-7) is critical for commitment
to B cell fate (Nagasawa, 2006), we initially focused on
changes in IL-7 production. Decreased Il7 transcription
was noted in OsxCre;iDTR mutant bones by qPCR (Fig-
ure S5A); however, IL-7 protein in the bone marrow sera
of mutants was not statistically decreased (Figure S5B).
This suggests that although Osx+ cell expresses IL-7, other
stromal cell types within the bone marrow likely produce
IL-7 when Osx+ cells are absent.
Among the measured cytokines, insulin-like growth
factor 1 (IGF-1) was notably decreased in our screen (Fig-
ure S5B). We confirmed that OsxCre;iDTR mutant bones
had decreased Igf1 transcripts compared with controls (Fig-
ure S5A). To determine what kind of hematopoietic cells
were the targets of the IGF-1 released by Osx+ cells, we as-
sessed flow sorted hematopoietic populations including
LINloSCA-1+C-KIT+ (LKS), CLP, common myeloid progeni-
tor (CMP), GMP, megakaryocyte-erythroid progenitor
(MEP), pro-B, pre-B, mature B, and LIN+ mature cells
by qPCR for IGF-1 receptor (IGF-1R) expression. IGF-1R
showed higher expression in LKS, CLP, pro-B, pre-B,
mature B, and LIN+ cells but not in CMP, GMP, and MEP
(Figure S5C), although the difference was not statistically
significant.
To further assess whether IGF-1 promotes B cell differen-
tiation, we evaluated hematopoietic cells from femurs of
the OsxCre;iDTRmutant and control mice bymethylcellu-
lose assays. Cells were grown with (1) no supplement, (2)
IL-7, (3) IGF-1, or (4) IL-7 + IGF-1 for a period of 14 days
and scored for CFU-G, CFU-M, CFU-GM, CFU-GEMM,
burst-forming unit (BFU)-E, and CFU-Pre-B (Figures S5D–
S5I). CFU-Pre-B assays showed that IL-7 promoted pre-B
colony formation, and the effect was further enhanced
when IGF-1 was added (Figure S5I). No positive effect on
the differentiation of other hematopoietic progenitors
was observed even when the combination of IL-7 and
IGF-1 was added (Figures S5D and S5F–S5H). However,
the addition of IL-7 and IGF-1 had a negative effect on
CFU-M (Figure S5E).
Our data suggest that Osx+ cells express IGF-1 to mediate
B cell differentiation. To validate this hypothesis in vivo,we
crossed the Osx1-GFP::Cre mouse with the B6.129(FVB)-
Igf1tm1Dlr/J (IGF-1F/F) strain, which has LoxP sites flanking
exon 4 of the Igf1 gene. Expression of Cre under the
Osx promoter in Osx1-GFP::Cre+;IGF-1F/F mice specif-
ically abolishes IGF-1 in Osx+ cells (Figure S6). Interest-228 Stem Cell Reports j Vol. 7 j 220–235 j August 9, 2016ingly, Osx1-GFP::Cre+;IGF-1F/F mutants showed increased
myeloid and decreased B lymphoid cells in the bone
marrow (Figure 6A), and decreased white blood cell counts
in the blood (Figure 6B), a phenotype reminiscent of the
Osx+ cell deletion mouse model. Strikingly, examination
of B cell development showed that cell maturation was
arrested at the pro-B to pre-B transition, a phenocopy of
the OsxCre;iDTR mutants, and the effect was even more
pronounced (Figure 6C). These data confirm that Osx+
cell regulates B cell development by providing IGF-1 to
enable B cell maturation.
Finally, we testedwhether the B cell differentiation defect
in the OsxCre;iDTR mutants could be rescued in vivo
by intravenous administration of recombinant IL-7 and
IGF-1. Both controls and mutants were subjected to daily
injections of DT, DT + IL-7, or DT + IGF-1 for 12 days. At
the end of the rescue regimen, bonemarrow cells were eval-
uated by flow cytometry (Figures 7A–7H). IL-7 administra-
tion increased the C0 and C00 pro-B populations (Figures 7C
and 7D) but did not rescue later B stages (Figures 7F–7H). In
contrast, IGF-1 had no effect at the early pro-B stages (Fig-
ures 7A–7E) but rescued the pre-B and mature B levels (Fig-
ures 7F–7H). These results suggest that while IL-7 supports
the differentiation of early B precursors, IGF-1 is required
for downstream B cell maturation and that Osx+ cells regu-
late this process via production of IGF-1.DISCUSSION
These and our recent publication (Yu et al., 2015a) demon-
strate thatmesenchymal cell populations in the niche have
stage-specific functional interactions with the hematopoi-
etic system. Specifically, while primitivemesenchymal cells
regulateHSC,wehave recently shownthatOcn+ cellsmodu-
late production of Tcells through the regulation of thymus-
seeding progenitors. Those data indicate that T lymphoid
progenitor specification and production were diminished
withOcn+ deletion; DLL4 was the identified Ocn+ cell prod-
uct responsible for the production of these Tcell precursors.
Here we show that specific steps of B cell differentiation are
affected by the partial loss of Osx+ cells. The importance of
osteolineage cells in regulating B cells within the bone
marrow has been known from reports documenting the
roles of IL-7 and CXCL12, among other factors (Ding and
Morrison, 2013; Greenbaum et al., 2013; Visnjic et al.,
2004; Wu et al., 2009; Zhu et al., 2007). Previous studies
reported that IGF-1 promotes B cell expansion in vitro
(Taguchi et al., 2006) and that activation of the IGF-1 recep-
tor is needed for immunoglobulin production (Baudler
et al., 2005). Local IGF-1productionmaybemost important
for marrow B lymphopoiesis, as prior studies of either liver
or pituitary-specific IGF-1 deficiency only observed altered
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Figure 6. Deletion of IGF-1 in Osx+ Cells Phenocopied OsxCre;iDTR Lymphoid Defects
To delete IGF-1 in Osx+ cells, we crossed the Osx1-GFP::Cre mouse with the IGF-1F/F strain.
(A) Osx1-GFP::Cre+;IGF-1F/F mutants showed increased Mac1+ and Gr1+ myeloid cells, and decreased B lymphoid cells in the bone marrow.
Three independent experiments; n = 8–14/group.
(B) Lymphopenia was also reflected in the peripheral blood. Experiment repeated once; n = 4–6/group.
(C) Osx1-GFP::Cre+;IGF-1F/F mutants showed a loss of mature B cells due to differentiation arrest at the pro-B to pre-B transition. Analysis
of B cell differentiation showed accumulation of cells at the B0, C0, and C00 pro-B cell stages, but decrease in number at the pre-B, immature
B, and mature B stages. Three independent experiments; n = 8–14/group.
*p < 0.05, **p < 0.01, ***p < 0.001. Error bars represent ± SEM.B cell numbers in the spleen and not within the bone
marrow (Montecino-Rodriguez et al., 1997; Welniak et al.,
2004). Our data indicate that osteoprogenitors secrete IL-7and IGF-1; both are necessary to support full B lineage dif-
ferentiation in the bone marrow (Figure 7I). Deletion of
Osx+ cells lead to minimal changes in IL-7 serum levelsStem Cell Reports j Vol. 7 j 220–235 j August 9, 2016 229
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Figure 7. Osx+ Cell Produces IL-7 and IGF-1 to Regulate B Cell Differentiation
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despite significant knockdown of Il7 transcripts. It is likely
that other cell types compensate for the production of
IL-7 in the niche. Rescue experiments showed that IGF-1
is required together with IL-7 to restore the full differentia-
tionprogramof B cells. These data suggest that IL-7 controls
early stages of B cell differentiation, in agreement with pre-
vious data (Tokoyoda et al., 2004), while IGF-1 is necessary
downstream of IL-7 for the differentiation into pro-B and
matureB cells. Taken together, our data suggest thatmarrow
B lymphopoiesis requires localized IGF-1 production while
extramedullary maturation is more affected by systemic
IGF-1.
Having defined through the triple transgenic model that
Osx+ cells are distinctive molecularly from Ocn+ cells, we
tested their selective function. The model we used was
intentionally of short duration to avoid the progression
of Osx+ cells to Ocn-expressing, ++ cells. In vivo, these cells
are dynamic and are lost after 90 days (Park et al., 2012).
Our data demonstrate that the Osx+ cells have no effect on
CLP or the Tcompetent progenitors, Ly6DCLP (Figure 4C)
in contrast to the Ocn+ cells. Nor do they produce DLL4 at
levels comparable with those in Ocn+ cells. However, they
do express abundant IL-7 and IGF-1 and through these
molecules regulate the maturation of B cell through the
pro-B cell stage. This maturation step is critical, as blunting
B cell progression by deleting Osx+ support cells resulted in
B lymphopenia and functional compromise of immuno-
globulin production.
Others have reported both B and Tcell effects after osteo-
lineage cell deletion (Ding and Morrison, 2013) but the
promoter used in some of those studies, Col1(2.3), extends
through many cell stages of osteolineage progression. Here
we define that these osteolineage cell states provide distinc-
tive functions in support of hematopoiesis through secre-
tion of specific regulatory molecules. Some of these effects
are in specific lineage production as noted inOcn+ cell dele-
tion (Yu et al., 2015a) and some are in lineage differentia-
tion as in the Osx+ deletion model.
It was notable that hematopoietic cell abnormalities in
deletion of either of these osteolineage subsets appeared
to be predominantly in the lymphoid compartment withpre-B and downstream B cell maturation (F–H). In contrast, IGF-1 had
B and mature B cell loss in the mutant group (F and H). Three indepe
0.0001.
(I) Model of regulation of B and T lymphopoiesis by Osx+ and Ocn+ osteo
are required to support full B lineage differentiation. While IL-7, also
differentiation from early B cell precursors to pre-B cells, Osx+ cell secre
mature B. In comparison, Ocn+ cell expresses the Notch ligand DLL4,
Ly6D CLP population (Yu et al., 2015a). This engagement ensures
molecules CCR7 and PSGL1 for subsequent thymic seeding. The precise
niche is critical for both B and T lymphopoiesis, as perturbation of th
Error bars represent ± SEM.little or no perturbation of HSC function. Nevertheless,
we encourage caution in interpreting the HSC data. Prior
reports by us (Calvi et al., 2003; Ferraro et al., 2011; Fleming
et al., 2008; Raaijmakers et al., 2010) and others (Visnjic
et al., 2004; Zhang et al., 2003) indicate a functional role
for osteolineage cells in HSPC regulation. A possible expla-
nation for the observed differences is that our cell depletion
was not 100% efficient. It is also possible that the lack
of functional defects in HSC, as demonstrated by the
serial transplantation experiment, could depend upon
the limited time donor HSCs were exposed to the mutated
microenvironment. Finally, we cannot rule out the possi-
bility that other cell types might have compensated for
the osteolineage cell loss, thus mitigating any HSC pheno-
type. In summary, whether HSC depend on osteolineage
cells deserves further clarification.
Several markers, including LEPTIN receptor (LEPR),
NESTIN, PDGFRb, CXCL12, PRX-1, CD105, and OSX,
have been described to label overlapping mesenchymal
stem cell populations with broad differentiation potential
in vivo (Yu and Scadden, 2016a, 2016b). In published
studies using OsxCreERt2, Osx+ cells did not overlap with
Nestin+ or LepR+ cells after short induction, but overlapped
highly after several weeks (Liu et al., 2013; Mizoguchi et al.,
2014; Ono et al., 2014). In addition, Osx+ cells have been
shown to contribute to osteogenic, adipogenic, and chon-
drogenic lineages upon injury in vivo and in the neonate,
but are restricted to the osteolineage in the adult (Mizogu-
chi et al., 2014). These inconsistent reports suggest that
these markers, rather than being cell specific, might reflect
functional states of mesenchymal cells that are dynamic
during development and tissue regeneration.We examined
the expression profile of these markers on Osx+ cells in our
model by microarray and flow cytometry. Osx+ cells iso-
lated from 6- to 8-week-old adults expressed low levels of
LEPR, NESTIN, and CD105, and low to intermediate levels
of PRX-1, CXCL12, and PDGFRb (Figures S7A and S7B). We
did not find extensive overlap in the Osx+ cells with LepR+
cells that might be considered CAR cells (Figures S7A and
S7B), despite others (Greenbaum et al., 2013) reporting
that some Osx+ cells overlaps with CAR cells as defined byno effect on earlier B cell differentiation (A–E), but rescued the pre-
ndent experiments; n = 6–9/group. *p < 0.05, **p < 0.01, ****p <
lineage cells. Osx+ cell produces IL-7 and IGF-1, and both molecules
likely produced by other stomal cell types, mediates hematopoietic
tion of IGF-1 is necessary for further B cell maturation from pre-B to
which binds to cell-surface Notch receptor on the T cell-competent
T cell progenitor production, and expression of the chemotactic
balance of Osx+ and Ocn+ osteolineage cells within the bone marrow
is balance leads to specific loss of B or T immune cells.
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the expression of CXCL12 (the age of the mice was not re-
ported). Nonetheless, our data cannot exclude the possibil-
ity of Osx+ cells being adipogenic in models with a longer
time chase, after injury or during perinatal life, although
we observed no evidence of adipocyte generation under
the conditions we studied.
There is a growing appreciation of a woven functional
architecture to the bone marrow space with mesenchymal
stem cells providing support for HSC (Mendez-Ferrer et al.,
2010), mature osteoblasts affecting HSC mobilization
by granulocyte colony-stimulating factor (Ferraro et al.,
2011), osteoprogenitors requiring microRNA processing
to maintain integrity of early and late hematopoiesis
(Raaijmakers et al., 2010), and Osx+ and Ocn+ cells having
key roles in B lymphoid differentiation and thymic hom-
ing progenitors (Yu et al., 2015a). The emerging model is
one of a highly interrelated system with ‘‘intermediate’’
populations of both skeleton and blood having very spe-
cific interactions. Whether these interactions are per-
turbed is of particular relevance in settings where specific
subsets of cells are deficient, such as in particular blood dis-
orders, or in the adaptive immune deregulation seen after
allogeneic bone marrow transplantation. Furthermore,
these heterologous cell interactions can now be explored
in malignant processes such as lymphoma, leukemia,
and bone metastatic processes. If the complexity of the
relationship between mesenchymal subsets of bone and
parenchymal subsets of blood is true in other organ types,
defining mesenchymal cells that comprise organ ‘‘stroma’’
may provide insight into parenchymal regulation and
dysfunction.EXPERIMENTAL PROCEDURES
Osteolineage Cell Deletion Mouse Models
TheOsx1-GFP::Cremouse strain (Rodda andMcMahon, 2006) was
crossed to the iDTR strain (Buch et al., 2005) to achieve Osx cell
deletion. These primers were used for genotyping: OsxCreF-
CTCTTCATGAGGAGGACCCT, OsxCreR-CAGGCAGGTGCCTGG
ACAT, oIMR8052-GCGAAGAGTTTGTCCTCAACC, oIMR8545-
AAAGTCGCTCTGAGTTGTTAT, oIMR8546-GGAGCGGGAGAAA
TGGATATG. OsxCre+;iDTR+/+ injected with DT or OsxCre+;
iDTRFl/+ injected with PBS were used as controls while OsxCre+;
iDTRFl/+ injected with DT were mutants. For most experiments,
100 ng of DT/g bodyweight (BW)was injected daily into both con-
trols and mutants from 4 to 6 weeks old to achieve an acute dele-
tion of specific osteolineage subsets. Mice were harvested the
next day after the last dose of DT injection. Injection regimen
had been prolonged to 4 weeks for phenotype comparison. For
all experiments, littermates were used as controls. C57BL/6J and
B6.SJL-PtprcaPepcb/BoyJ (SJL) strains were obtained from Jackson
Laboratories. All animal use and procedures performed were
approved by the Institutional Animal Care and Use Committee
of Massachusetts General Hospital.232 Stem Cell Reports j Vol. 7 j 220–235 j August 9, 2016Bone Histomorphometry
Paraffin sections of long bones were stained with H&E, von
Kossam, and Goldner trichrome, and analyzed using BioQuant
software. Statistical analysis was performed using the non-para-
metric Mann-Whitney test. TRAP staining was used to reveal oste-
oclasts. Osteolineage activity was assessed by measuring serum
levels of OCN and N-terminal propeptide of type I procollagen
(P1NP) using RatLaps ELISA kits. Bone resorption was assessed by
measuring theC-terminal telopeptides of collagen type I fragments
in mouse serum using the RatLaps EIA kit.
Immunohistochemistry
Expression of the DT receptor was detected by immunohistochem-
istry using an anti-human heparin-binding EGF-like growth factor
(anti-hHB-EGF) antibody. In brief, paraffin sections were treated
with 0.1% trypsin and 3% H2O2, and blocked with reagent con-
taining 5% animal serum in PBS + Tween 20 for 1 hr. Anti-hHB-
EGF antibody (R&D Systems MAB391, 1:25 dilution) was used as
primary antibody coupled with biotinylated IgG secondary anti-
body (Vector Laboratories BA-9500, 1:400 dilution). After staining,
sections were treated with a Vectastain ABC Kit for biotin-strepta-
vidin signal amplification and visualized by a DAB Peroxidase
Substrate Kit. Osx+ cells were detected by staining sections with
anti-SP7 antibody (Abcam Ab22552, 1:2,000 dilution) coupled
with secondary antibody conjugated to Alexa Fluor 488 (Thermo
Fisher Scientific A27034, 1:1,000 dilution). Ocn+ cells were
recognized by anti-OCN antibody (Santa Cruz Biotechnology
SC18322, 1:50 dilution) followed by secondary antibody conju-
gated to Alexa Fluor 488 (Thermo Fisher A11078, 1:1,000 dilution).
Green fluorescent OSX- or OCN-antibody staining was then indi-
vidually superimposed with red fluorescent TUNEL staining (In
Situ Cell Death Detection Kit TMR Red, Roche Applied Science).
Microarray Data
Microarray analysis was performed as previously described (Yu
et al., 2015b). The Accession number is GEO: GSE66042.
CFU-Ob Assay
TheCFU-Ob assay was performed as previously described (Yu et al.,
2015a).
Flow Cytometry
Peripheral blood from each mouse was subjected to complete
blood count. Tibias, femurs, iliac crests, spines, ulnae, radii, and
humeri were harvested for bone marrow cells. Spleen and thymus
were collected for lymphocyte staining. Flow cytometry staining
for all hematopoietic subpopulations including T cell develop-
mental stages was performed as previously described (Yu et al.,
2015a). For B cell development, the following scheme was used:
B220-Pacific Blue (BD Biosciences 558108), IgM-PE-Cy5 (eBio-
sciences 15-5790-82), CD43-fluorescein isothiocyanate (FITC)
(eBiosciences 11-0431-82), CD24-APC (Biolegend 101814), and
BP1-PE (eBiosciences 12-5891-83). Definitions of stages of B cell
maturation were as follows: A0 pre-pro-B (IgMB220+CD43+
BP1CD24), B0 pro-B (IgMB220+CD43+BP1CD24+), C0 pro-B
(IgMB220+CD43+BP1+CD24lo), C00 pro-B (IgMB220+CD43+BP1+
CD24hi), pro-B (IgMB220+CD43+), pre-B (IgMB220+CD43),
B progenitors (IgMB220+), immature B (IgM+B220lo), and mature
B (IgM+B220hi). For cell-cycle analysis, bromodeoxyuridine-FITC
and 7AAD, or Ki67-FITC and DAPI staining were coupled with
staining of specific populations to reveal their cell-cycle status.
Anti-inflammatory Assay
Indomethacin was injected at 2.5 mg/kg BW daily along with DT
throughout the deletion regimen. Mice were euthanized the next
day following the last injection. Bone marrow was harvested
from femurs, tibias, iliac crests, and spines. After lysis of red blood
cells, bone marrow cells were stained with antibodies against
monocytes and granulocytes (Mac1, Gr1), macrophages (Mac1),
and granulocyte macrophage progenitors (CD127, LIN, SCA-1,
C-KIT, CD34, CD16/32) for flow cytometricmeasurement as previ-
ously described (Yu et al., 2015a).
Immune Response Assay
After 1 week of DT injection (day 0), mice were injected
with 0.1 mg/ml NP28-AECM-Ficoll/PBS intraperitoneally to trigger
T cell-independent Ig production. In this assay, DT injection
continued throughout the next 28 days. Mice were re-immunized
with a second boost of NP28-AECM-Ficoll at day 14. Mice were
bled at days 0, 7, 14, 21, and 28. Sera collected from control and
mutant animals were subjected to measurement of IgG and IgM
levels by ELISA following standard protocol.
Transplantation
For transplantation of wild-type cells into mutant environment,
13 106 bone marrow cells from 6-week-old SJL donors were trans-
planted into each of ten age-matched 9.5-Gy lethally irradiated
OsxCre+;iDTR+/+ control or OsxCre+;iDTRFl/+ mutant recipients.
DT injection into both control and mutant recipients began at
7 days before transplantation and were maintained every alternate
day until 12weeks post transplant. Recipientswere bled at 4, 8, and
12 weeks post transplant. Peripheral blood was subjected to com-
plete blood cell count and reconstitution analysis as previously
published (Yu et al., 2015a). All recipients were euthanized at
12 weeks post transplant. Bone marrow cells were harvested from
femurs, tibias, and iliac crests, and subjected to lineage reconstitu-
tion analysis as described previously (Yu et al., 2015a). For trans-
plantation of mutant cells into wild-type recipients, 5 3 105 bone
marrow cells from 6-week-old mutant OsxCre+;iDTRFl/+ or control
OsxCre+;iDTRFl/+ donorswere competedwith53105bonemarrow
cells from age-matched SJL mice. For both controls and mutants, a
total of 13106mixeddonorcellswere transplanted intoeachof ten
9.5-Gy irradiated SJL recipients. Recipientswere bled at 4, 8, 12, and
16 weeks post transplant. Peripheral blood was subjected to com-
plete blood cell count and reconstitution analysis by flow cytome-
try as reported by Yu et al. (2015a). At 16 weeks post transplant, all
recipients were euthanized. Bone marrow cells were subjected to
lineage reconstitution analysis as described by Yu et al. (2015a).
Cytokine Array
Bones with both ends excised were centrifuged at 12,000 rpm for
1min for bonemarrow extraction. Each sample was further centri-
fuged at 6,000 rpm for 10 min for serum isolation, and stored
at 20C until use. For measurement of cytokines in circula-tion, 200 ml of peripheral blood was collected, centrifuged at
6,000 rpm for 10 min for serum isolation, and stored at 20C un-
til use. A 1/5 dilution of each serum samplewas subjected to RayBio
Mouse Cytokine Antibody Array G Series 4 (RayBiotech, AAM-
CYT-G4-4) (n = 24 per group).
qPCR
Positive hits of cytokine array were validated by qPCR using the
GAPDH gene for normalization. Various sources were used for
RNA extraction: total bone marrow cells of mutant or control
mice, flushed femoral bone of mutant or control mice, and flow
sorted cells of stained hematopoietic populations including LKS,
CLP, CMP, GMP, MEP, Pro-B, Pre-B, Mature B, and Lineage+ cells.
Rescue Experiments
For in vitro rescue experiments, bone marrow cells were harvested
from femurs and tibias of OsxCre;iDTR controls or mutants and
plated at 2 3 104 in each well of a six-well plate with methylcellu-
lose-containing medium, supplemented with 100 ng/ml IL-7,
100 ng/ml IGF-1, or both IL-7 and IGF-1. Cells were incubated at
5% CO2 at 37
C undisturbed and enumerated for progenitor col-
onies by day 8 or day 14. For in vivo rescue experiments, control
and mutant OsxCre;iDTR mice were intraperitoneally injected
with (1) 100 ng/g BW DT alone, (2) DT and 250 ng/g BW recombi-
nant murine IL-7, and (3) DT and 1 mg/g BW recombinant mouse
IGF-1 daily for 12 days. IL-7 and IGF-1 were injected intravenously.
Mice were euthanized for bone marrow cell harvest. Cells were
stained for GMP- and B cell development-specific antibodies for
flow cytometric analysis.
Statistical Analysis
Statistical analysis of all paired experiments was analyzed by two-
tailed Student’s t test, unless otherwise stated. Data in all graphs
represent the mean and SEM where *p < 0.05, **p < 0.01, and
***p < 0.001. Statistical comparison of multiple parameters were
analyzed by one-way ANOVA followed by Bonferroni post test,
where *p < 0.05, **p < 0.01, and ***p < 0.001.
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